Table 1.

Biosimilar drugs in Europe^*.

Medicine name	Active substance	Manufacturer	Status	Year of authorisation/withdrawal/refusal
Omnitrope®	Somatropin	Sandoz GmbH	Authorized	2006
Valtropin®	Somatropin	BioPartners GmbH	Withdrawn	2006
Alpheon	Recombinant Human Interferon α-2a	BioPartners GmbH	Refused	2006
Abseamed®	Epoetin α	Medice Arzneimittel Pütter GmbH & Co. KG	Authorized	2007
Binocrit®	Epoetin α	Sandoz GmbH	Authorized	2007
Epoetin Alpha Hexal®	Epoetin α	Hexal AG	Authorized	2007
Retacrit™	Epoetin Zeta	Hospira UK Ltd	Authorized	2007
Silapo®	Epoetin Zeta	Stada Arzneimittel AG	Authorized	2007
Biograstim®	Filgrastim	AbZ-Pharma GmbH	Authorized	2008
Filgrastim ratiopharm®	Filgrastim	Ratiopharm GmbH	Withdrawn	2008
Ratiograstim®	Filgrastim	Ratiopharm GmbH	Authorized	2008
Tevagrastim®	Filgrastim	Teva GmbH	Authorized	2008
Filgrastim Hexal®	Filgrastim	Hexal AG	Authorized	2009
Zarzio®	Filgrastim	Sandoz GmbH	Authorized	2009
Nivestim™	Filgrastim	Hospira UK Ltd.	Authorized	2010
Grastofil	Filgrastim	Apotex Europe B.V.	Authorized	2013
Ovaleap®	Follitropin α	Teva Pharma B.V.	Authorized	2013
Inflectra™	Infliximab	Hospira UK Ltd	Authorized	2013
Remsima™	Infliximab	Celltrion Healthcare Hungary Kft.	Authorized	2013
Bemfola	Follitropin α	Finox Biotech AG	Authorized	2014
Abasria®	Insulin glargine	Eli Lilly and Company and Boehringer Ingelheim	Authorized	2014

^*European Medicines Agency ²⁷.